John Hood
John Hood has found another misfit drug to love — and bring back from the dead
Taladegib, an inhibitor of the chronic Hedgehog signaling pathway, died a slow and remorseless death.
Eli Lilly licensed it out to Jonathan Lim’s Ignyta in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
